Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department

NCT ID: NCT01947127

Last Updated: 2016-12-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

458 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-03-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the role of initial venous lactate in predicting the severity progression to overt septic shock and 30-day mortality in non-elderly patients without hemodynamic shock who suspected to have acute infections.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Blood lactate is one of the markers that can predict the organ failures and mortality in emergency department (ED) patients with sepsis. Regarding its predictive role in the clinical deterioration in normotensive sepsis patients, a recent prospective observational study of the patients with moderately-high serum lactate (2.0-3.9 mmol/L) showed that one-forth of the patients eventually developed progressive organ dysfunctions or required vasopressor or mechanical ventilator. Unfortunately, low serum lactate (\< 2.5 mmol/L) was still found up to 50% of overt septic shock patients, even in vasopressor-dependent cases. For the prognostic role on mortality, numbers of articles showed that blood lactate can also predict death in sepsis patients, especially in those who are elderly and critically-ill. However, no previous study was done in younger patients since lactate kinetics in the body may differ among the age groups. The primary aim of our study is to investigate the role of initial venous lactate levels in predicting the chance of severity progression to overt septic shock especially in non-elderly patients who suspected to have acute infections and without hemodynamic shock in ED. The secondary outcomes are to evaluate its prognostic role on hospital length of stay and 30-day mortality of this target population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Disease Progression Septic Shock Fatal Outcome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High lactate

Initial venous lactate level equal to or more than 2.0 mmol/L

No interventions assigned to this group

Low lactate

Initial venous lactate level less than 2.0 mmol/L

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 65 years
* Confirmed or suspected diagnoses of acute infections (within 7 days)
* Major infections (e.g. Acute pyelonephritis, Acute bronchitis/pneumonia, Acute hepatobiliary tract infections, intrabdominal abscesses, meningitis and other central nervous system infections, soft tissue infections involving more than 10 square centimeters of the skin surface or deeper down beyond the dermis, significant tropical infections; dengue fever, leptospirosis, typhus fevers, or high fever from any infectious sources)
* Systolic blood pressure more than 90 mmHg at presentation
* Mean arterial pressure more than 70 mmHg at presentation

Exclusion Criteria

* Duplicated cases that have participated in this study during the study period
* Overt organ hypoperfusion (e.g. cold, clammy or mottling skin, altered mental status; Glasgow Coma Scale equal to or less than 12 or decrease \> 1 compared with the baseline)
* Pulse oximetry equal to or less than 90% at ambient air
* received intravenous fluid more than 10 ml/kg prior to the venous blood sampling
* received intravenous antibiotics for more than 1 hours prior to the venous blood sampling
* Minor infections (e.g. uncomplicated upper respiratory tract infections, gastroenteritis, minor skin infections)
* currently taking antiretroviral drugs
* having or suspicious of having seizures in the past 72 hours
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chulalongkorn University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Khrongwong Musikatavorn, MD.

Khrongwong Musikatavorn, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Khrongwong Musikatavorn, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Medicine, Facalty of medicine, Chulalongkorn University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Emergency Medicine Unit, King Chulalongkorn Memorial Hospital

Patumwan, Bangkok, Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

References

Explore related publications, articles, or registry entries linked to this study.

Musikatavorn K, Thepnimitra S, Komindr A, Puttaphaisan P, Rojanasarntikul D. Venous lactate in predicting the need for intensive care unit and mortality among nonelderly sepsis patients with stable hemodynamic. Am J Emerg Med. 2015 Jul;33(7):925-30. doi: 10.1016/j.ajem.2015.04.010. Epub 2015 Apr 10.

Reference Type RESULT
PMID: 25936479 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

793/2012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lactate Kinetics in Septic Shock
NCT05349370 RECRUITING NA
Fluid Resuscitation in Early Septic Shock
NCT00819416 COMPLETED PHASE2
Methylene Blue in Early Septic Shock
NCT04446871 COMPLETED PHASE2/PHASE3